

# RÃ©gis T Costello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4352271/publications.pdf>

Version: 2024-02-01

91  
papers

3,037  
citations

172457

29  
h-index

168389

53  
g-index

102  
all docs

102  
docs citations

102  
times ranked

3819  
citing authors

#	ARTICLE	IF	CITATIONS
1	Defective expression and function of natural killer cellâ€“triggering receptors in patients with acute myeloid leukemia. <i>Blood</i> , 2002, 99, 3661-3667.	1.4	434
2	Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. <i>Blood</i> , 2007, 109, 323-330.	1.4	321
3	The TNF Superfamily Members LIGHT and CD154 (CD40 Ligand) Costimulate Induction of Dendritic Cell Maturation and Elicit Specific CTL Activity. <i>Journal of Immunology</i> , 2001, 167, 2479-2486.	0.8	163
4	Reciprocal Expression of the TNF Family Receptor Herpes Virus Entry Mediator and Its Ligand LIGHT on Activated T Cells: LIGHT Down-Regulates Its Own Receptor. <i>Journal of Immunology</i> , 2000, 165, 4397-4404.	0.8	161
5	Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: Engagement of CD33 induces apoptosis of leukemic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5764-5769.	7.1	100
6	Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. <i>European Journal of Immunology</i> , 1998, 28, 90-103.	2.9	78
7	Primary plasma cell leukaemia: a report of 18 cases. <i>Leukemia Research</i> , 2001, 25, 103-107.	0.8	78
8	What is the real role of CD40 in cancer immunotherapy?. <i>Trends in Immunology</i> , 1999, 20, 488-493.	7.5	75
9	Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33?q34. <i>Immunogenetics</i> , 1990, 31, 198-201.	2.4	72
10	NK cells: innate immunity against hematological malignancies?. <i>Trends in Immunology</i> , 2004, 25, 328-333.	6.8	65
11	Human immunodeficiency virusâ€“related lymphoma: relation between clinical features and histologic subtypes. <i>American Journal of Medicine</i> , 2001, 111, 704-711.	1.5	62
12	Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. <i>Blood</i> , 2005, 106, 2186-2188.	1.4	60
13	LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T cell-dependent B cell terminal differentiation. <i>European Journal of Immunology</i> , 2004, 34, 3534-3541.	2.9	56
14	The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. <i>European Journal of Immunology</i> , 2006, 36, 2359-2366.	2.9	55
15	Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. <i>Immunology</i> , 2013, 139, 338-341.	4.4	54
16	Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 431-441.	4.5	54
17	Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	52
18	MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. <i>Thrombosis and Haemostasis</i> , 2013, 110, 844-851.	3.4	52

#	ARTICLE	IF	CITATIONS
19	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2017, 31, 2493-2501.	2.2	51
20	Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. <i>Immunology</i> , 2012, 135, 151-157.	4.4	44
21	The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4+ T cells. <i>European Journal of Immunology</i> , 1993, 23, 608-613.	2.9	43
22	The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38â leukemic progenitors. <i>Leukemia</i> , 1999, 13, 1513-1518.	7.2	41
23	Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. <i>Leukemia</i> , 2003, 17, 2500-2507.	7.2	40
24	Detection of CBFÎ²/MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics. <i>Leukemia</i> , 1997, 11, 644-650.	7.2	38
25	Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1-13.	4.2	38
26	Gaucher disease and multiple myeloma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1365-1368.	1.3	35
27	A role for HVEM, but not lymphotoxinâ2 receptor, in LIGHTâinduced tumor cell death and chemokine production. <i>European Journal of Immunology</i> , 2009, 39, 2502-2514.	2.9	33
28	Philadelphia chromosomeânegative chronic myeloid leukaemia: a report of 14 new cases. <i>British Journal of Haematology</i> , 1995, 90, 346-352.	2.5	30
29	Natural Killer Cells Modulation in Hematological Malignancies. <i>Frontiers in Immunology</i> , 2013, 4, 459.	4.8	29
30	Clinical and biological aspects of philadelphia-Negative/BCR-Negative chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 1997, 25, 225-232.	1.3	28
31	Translocation of BCR to chromosome 9 in a Philadelphia-negative chronic myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1995, 85, 82-84.	1.0	25
32	Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. <i>Leukemia and Lymphoma</i> , 1996, 20, 239-243.	1.3	25
33	New approaches in the immunotherapy of haematological malignancies. <i>European Journal of Haematology</i> , 2003, 70, 333-345.	2.2	23
34	Unbalanced translocation t(5;17) in an atypical acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 307-312.	2.8	22
35	LIGHT, a new TNF superfamily member, is essential for memory T helper cell-mediated activation of dendritic cells. <i>European Journal of Immunology</i> , 2003, 33, 3213-3219.	2.9	21
36	Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. <i>Annals of Oncology</i> , 1999, 10, 362-363.	1.2	20

#	ARTICLE	IF	CITATIONS
37	Mechanisms Regulating Expression of the Tumor Necrosis Factor-related light Gene. <i>Journal of Biological Chemistry</i> , 2002, 277, 42841-42851.	3.4	20
38	Therapeutic Use of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): A review of recent experience. <i>Acta OncolÃ³gica</i> , 1993, 32, 403-408.	1.8	19
39	A novel mechanism of antitumor response involving the expansion of CD3+/CD56+ large granular lymphocytes triggered by a tumor-expressed activating ligand. <i>Leukemia</i> , 2002, 16, 855-860.	7.2	19
40	Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 223-225.	1.3	18
41	The Philadelphia chromosome as a secondary abnormality in two cases of acute myeloid leukemia. <i>British Journal of Haematology</i> , 1998, 102, 873-875.	2.5	17
42	Natural Killer Cell-triggering Receptors in Patients with Acute Leukaemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 1683-1689.	1.3	17
43	Peripheral TÃ©cell lymphoma gene expression profiling and potential therapeutic exploitations. <i>British Journal of Haematology</i> , 2010, 150, 21-27.	2.5	17
44	Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. <i>European Journal of Internal Medicine</i> , 2019, 68, 71-75.	2.2	16
45	Minor breakpoint cluster region (m-BCR) positive chronic myeloid leukaemia with an acute lymphoblastic leukaemia onset: a case report. <i>British Journal of Haematology</i> , 1995, 91, 428-430.	2.5	15
46	Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus. <i>Cancer</i> , 2004, 100, 667-676.	4.1	15
47	Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue. <i>Annals of Hematology</i> , 2021, 100, 2799-2803.	1.8	14
48	Acute myeloid leukaemia triggering via CD40 induces leukocyte chemoattraction and cytotoxicity against allogenic or autologous leukemic targets. <i>Leukemia</i> , 2000, 14, 123-128.	7.2	13
49	Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center. <i>Bone Marrow Transplantation</i> , 2000, 25, 35-40.	2.4	12
50	Three-year outcome in a patient with <i>Staphylococcus lugdunensis</i> discitis. <i>Joint Bone Spine</i> , 2002, 69, 85-87.	1.6	12
51	Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients During the Combined Antiretroviral Therapy Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 249-253.	2.1	12
52	Third case of acute monocytic leukemia (M5) occurring in an HIV-Seropositive man: A case report. <i>American Journal of Hematology</i> , 1995, 49, 356-357.	4.1	11
53	Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols. <i>Lancet Oncology</i> , The, 2004, 5, 47-55.	10.7	10
54	Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP1Ã©likeÃ©plateletÃ©derived growth factor receptor alpha fusion gene. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 234-234.	2.4	10

#	ARTICLE	IF	CITATIONS
55	The contribution of single-cell analysis of acute leukemia in the therapeutic strategy. <i>Biomarker Research</i> , 2021, 9, 50.	6.8	9
56	Bone marrow necrosis and sickle cell crisis associated with double heterozygosity for HbS and HbOARAB. <i>American Journal of Hematology</i> , 2011, 86, 309-310.	4.1	8
57	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. <i>Aids</i> , 2020, 34, 599-608.	2.2	7
58	Rank ligand stimulation induces a partial but functional maturation of human monocyte-derived dendritic cells. <i>European Cytokine Network</i> , 2008, 19, 81-8.	2.0	7
59	Leukopenia, thrombocytopenia, and acute autoimmune hemolytic anemia associated with an unusual (type 2/4) Hodgkin's disease: Case report. , 1996, 52, 333-334.		6
60	First case of plasma-cell leukemia co-existing with human immunodeficiency virus infection. <i>Leukemia</i> , 1998, 12, 103-104.	7.2	6
61	Rapid evolution of multiple myeloma after cobalamin therapy for megaloblastic erythropoiesis with macrocytic anemia. <i>Leukemia Research</i> , 1998, 22, 287.	0.8	6
62	Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of SÃ©zary T lymphoma: a transcriptomic approach. <i>Archives of Dermatological Research</i> , 2017, 309, 611-623.	1.9	6
63	Intensive chemotherapy with rituximab is safe and effective in AIDS non-Hodgkin's lymphoma. <i>Aids</i> , 2003, 17, 2006-2007.	2.2	5
64	Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients. <i>AIDS Research and Therapy</i> , 2014, 11, 38.	1.7	5
65	A transcriptomic signature predicting septic outcome in patients undergoing autologous stem cell transplantation. <i>Experimental Hematology</i> , 2018, 65, 49-56.	0.4	5
66	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. <i>British Journal of Haematology</i> , 2020, 188, 413-423.	2.5	5
67	High Serum Vitamin B12 Levels Associated with C-reactive Protein in Older Patients with Cancer. <i>Oncologist</i> , 2020, 25, e1980-e1989.	3.7	5
68	Askin Tumor and Acute Myeloid Leukemia in a Patient with Constitutional Partial Y Disomy. <i>Cancer Genetics and Cytogenetics</i> , 1998, 103, 11-14.	1.0	4
69	Distribution of lymphocyte subpopulations in patients with polycythemia vera. <i>Human Immunology</i> , 2015, 76, 414-416.	2.4	4
70	Identification of a myeloma variant with aggressive biological and clinical characteristics: "Early" plasma cell meningitis. , 1997, 56, 295-296.		3
71	Agranulocytosis occurring in a patient with chronic lymphocytic leukemia in complete remission; treatment by rituximab and cyclosporin. <i>Leukemia Research</i> , 2010, 34, e329-e330.	0.8	3
72	Recurrent hepatic hematoma due to familial lysozyme amyloidosis resolves with conservative management. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 66-68.	3.0	3

#	ARTICLE	IF	CITATIONS
73	Natural killer cells in patients with polycythemia vera. <i>Human Immunology</i> , 2015, 76, 644-650.	2.4	3
74	Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?â€”Potential therapeutic applications. <i>European Journal of Haematology</i> , 2021, 106, 589-592.	2.2	3
75	Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e503-e505.	0.4	3
76	Immune reconstitution during intensive chemotherapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma. <i>The Hematology Journal</i> , 2002, 3, 216-218.	1.4	3
77	Maladie de Horton et leucÃ©mie lymphoÃ©de chronique. <i>Revue De Medecine Interne</i> , 1992, 13, 472.	1.0	2
78	How to restore normal innate antitumor immunity in acute leukemia?. <i>Leukemia Research</i> , 2009, 33, 613.	0.8	2
79	Macrophage colony-stimulating factor production in leukemic cell lines compared to normal T cells. <i>Leukemia Research</i> , 1992, 16, 723.	0.8	1
80	Pseudo-â€œacid retinoic syndromeâ€”mimicked by severe influenza A infection. <i>American Journal of Hematology</i> , 1996, 52, 120-120.	4.1	1
81	Non-Hodgkin's lymphoma after kidney transplantation: A single institution study. <i>Leukemia Research</i> , 2006, 30, 118-119.	0.8	1
82	Recurrent superior vena cava syndrome caused by IgD multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 1977-1978.	1.8	1
83	Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts. <i>Leukemia Research Reports</i> , 2015, 4, 15-17.	0.4	1
84	Is R-CHOP Therapy a Lymphoma Growth Factor?. <i>American Journal of Therapeutics</i> , 2016, 23, e295-e297.	0.9	1
85	Good outcome after rituximab treatment for a mixed warm and cold autoimmune haemolytic anaemia. <i>BMJ Case Reports</i> , 2009, 2009, bcr0920080857-bcr0920080857.	0.5	1
86	Natural killer cells and immunity against cancer. <i>Discovery Medicine</i> , 2004, 4, 333-7.	0.5	1
87	INTERLEUKIN 2 AND ITS PLEIOTROPIC EFFECTS. <i>British Journal of Haematology</i> , 1991, 79, 345-345.	2.5	0
88	Pretransplantation Blood Transfusion. <i>New England Journal of Medicine</i> , 1992, 326, 1027-1028.	27.0	0
89	Granular lymphoproliferative disorder, autologous blood stem cell transplantation and multiple myeloma. <i>European Journal of Haematology</i> , 2003, 71, 311-312.	2.2	0
90	Reversing the multidrug resistance in acute leukemia: Until the leukemia initiating cell?. <i>Leukemia Research</i> , 2009, 33, 749.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Natural killer cells in leukaemia. , 2010, , 533-541.		0